头孢哌酮/三唑巴坦对临床分离产酶菌的体外抗菌活性

In vitro antibacterial activity of cefoperazone combined with tazobactam against clinical isolates producing β-lactamases

目的 评价头孢哌酮 /三唑巴坦 (8∶ 1)对产酶菌的体外抗菌活性。方法 采用琼脂平板二倍稀释法测定头孢哌酮 /三唑巴坦 (8∶ 1)复方制剂对临床分离致病菌的体外抗菌作用 ,并与头孢哌酮、头孢哌酮 /舒巴坦 (1∶ 1)和哌拉西林 /三唑巴坦 (8∶ 1)进行比较。结果 头孢哌酮与三唑巴坦 (8∶ 1)复方制剂可不同程度的提高头孢哌酮单用的体外抗菌活性 ,与头孢哌酮 /舒巴坦 (1∶ 1)和哌拉西林 /三唑巴坦 (8∶ 1)的抗菌活性相似。结论 三唑巴坦增强了头孢哌酮对β-内酰胺酶的稳定性 ,头孢哌酮 /三唑巴坦 (8∶ 1)

Objective: To evaluate the in vitro antibacterial activity of combined formulation of cefoperazone (CPZ) tazobactam (TB) (8∶1) against β lactamases producing bacteria. Methods: The minimal inhibitory concentrations (MICs) of CPZ/TB (8∶1) to the bacteria isolated from clinical department were determined by standard agar dilution method and compared with the MICs of CPZ, cefoperazone (CPZ)/sulbactam (SB) (1∶1) and piperacillin (PIPC)/TB (8∶1). Results: The antibacterial activity of CPZ combined with TB was superior to CPZ alone and similar to CPZ/SB (1∶1) and PIPC/TB (8∶1). Conclusion: The combined formulation of CPZ and TB (8∶1) against β lactamases is improved and antibacterial activities are enhanced .